| 0 (0%) | 10-12 19:13 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.88 |
1-year : | 2.19 |
| Resists | First : | 1.61 |
Second : | 1.88 |
| Pivot price | 1.32  |
|||
| Supports | First : | 1.33 |
Second : | 1.15 |
| MAs | MA(5) : | 1.3 |
MA(20) : | 1.36 |
| MA(100) : | 1.71 |
MA(250) : | 2.66 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 41.1 |
D(3) : | 34.2 |
| RSI | RSI(14): 50.6 |
|||
| 52-week | High : | 5.88 | Low : | 1.07 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BGLC ] has closed below upper band by 31.6%. Bollinger Bands are 23.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.43 - 1.44 | 1.44 - 1.44 |
| Low: | 1.3 - 1.3 | 1.3 - 1.31 |
| Close: | 1.38 - 1.39 | 1.39 - 1.4 |
Wed, 07 Oct 2026
BioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI Licence - FinancialContent
Wed, 07 Oct 2026
BGLC 8-K & SEC Filings - Yahoo Finance
Mon, 05 Oct 2026
RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab - FinancialContent
Thu, 10 Sep 2026
BioNexus (BGLC) Stock Analysis: Climbs +3.57%, Eyes on $1.52 2026-09-10 - Merger Arbitrage - www.dars.gov.et
Fri, 28 Aug 2026
BGLC Defends Handling Of Staff Relations Following Concerns - Radio Jamaica News
Thu, 27 Aug 2026
BGLC Workers Raise Concerns About Planned Merger, Other Issues - Radio Jamaica News Online
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 3 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 44.7 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 10 (K) |
| Shares Short P.Month | 7 (K) |
| EPS | -1.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.22 |
| Profit Margin | -82.4 % |
| Operating Margin | -398.7 % |
| Return on Assets (ttm) | -19 % |
| Return on Equity (ttm) | -33.7 % |
| Qtrly Rev. Growth | -96.6 % |
| Gross Profit (p.s.) | 0.13 |
| Sales Per Share | 1.06 |
| EBITDA (p.s.) | -0.91 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -1.11 |
| PEG Ratio | 0 |
| Price to Book value | 0.43 |
| Price to Sales | 1.3 |
| Price to Cash Flow | -4.81 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|